Announcements Trials
Browse Landscape

Phase

Phase 4 5Phase 3 5Phase 2 3

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Ductal Adenocarcinoma 1Glioma 1Behavior, Addictive 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER × Escitalopram × Clear all
NCT03728673 2026-04-17

A Study Utilizing Escitalopram in Glioma Patients

University of Nebraska

Phase 2 Recruiting
20 enrolled
CNS

Glioma

NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
4 enrolled 10 charts
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT03010761 2019-07-24

Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer

China Medical University Hospital

Phase 2 Terminated
90 enrolled

Behavior, Addictive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡